Neurodegenerative Disorder Therapeutics Market By Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, and Other Indication Types), By Drug Type (N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, and Other Drug Types), By Distribution (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis, and Forecast till 2029

Market for treatments for neurodegenerative disorders was valued at US$ 9.32 billion in 2019 and is projected to grow at a compound annual growth rate of 8.7% to reach US$ 21.3 billion by 2029.

A class of conditions known as neurodegenerative illnesses impact the central nervous system. They include both inherited and random disorders that are characterized by a slow, progressive, irreversible nervous system malfunction accompanied by neuronal enlargement and degeneration. It results in symptoms like movement dysfunction, memory loss, and cognitive decline. Neurodegenerative diseases are incurable at this time. In order to lessen the intensity of symptoms and slow the disease's progression, treatment focuses on controlling the disease's indication.